All approv_老虎社区_美港股上老虎

MT8
2021-11-17

All approved and ship out soon! :)

Philippines approves emergency use of Novavax COVID-19 vaccine

MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by N

Philippines approves emergency use of Novavax COVID-19 vaccine

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":878964107,"tweetId":"878964107","gmtCreate":1637140195078,"gmtModify":1637140197735,"author":{"id":3575026781055696,"idStr":"3575026781055696","authorId":3575026781055696,"authorIdStr":"3575026781055696","name":"MT8","avatar":"https://static.tigerbbs.com/3e8beecc1c281197b1551a2353b1204e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>All approved and ship out soon! :)</p></body></html>","htmlText":"<html><head></head><body><p>All approved and ship out soon! :)</p></body></html>","text":"All approved and ship out soon! :)","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/878964107","repostId":2184833364,"repostType":2,"repost":{"id":"2184833364","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637125658,"share":"https://www.laohu8.com/m/news/2184833364?lang=&edition=full","pubTime":"2021-11-17 13:07","market":"us","language":"en","title":"Philippines approves emergency use of Novavax COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2184833364","media":"Reuters","summary":"MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by N","content":"<p>MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc , its food and drug agency chief said on Wednesday, the ninth vaccine approved in the Southeast Asian country.</p>\n<p>The nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above, the agency's chief Rolando Enrique Domingo told a public briefing.</p>\n<p>Covovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.</p>\n<p>The Philippines has inoculated more than a quarter of its 110 million population.</p>\n<p>Early this month, Novavax received its first emergency use authorisation&nbsp;from Indonesia. Novavax also filed an application for approval of the vaccine in Canada and with the European Medicines Agency.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philippines approves emergency use of Novavax COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilippines approves emergency use of Novavax COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-17 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc , its food and drug agency chief said on Wednesday, the ninth vaccine approved in the Southeast Asian country.</p>\n<p>The nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above, the agency's chief Rolando Enrique Domingo told a public briefing.</p>\n<p>Covovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.</p>\n<p>The Philippines has inoculated more than a quarter of its 110 million population.</p>\n<p>Early this month, Novavax received its first emergency use authorisation&nbsp;from Indonesia. Novavax also filed an application for approval of the vaccine in Canada and with the European Medicines Agency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184833364","content_text":"MANILA, Nov 17 (Reuters) - The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc , its food and drug agency chief said on Wednesday, the ninth vaccine approved in the Southeast Asian country.\nThe nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above, the agency's chief Rolando Enrique Domingo told a public briefing.\nCovovax, which had efficacy of 89.7% in clinical trials, will be administered in two doses not less than 21 days apart, Domingo added.\nThe Philippines has inoculated more than a quarter of its 110 million population.\nEarly this month, Novavax received its first emergency use authorisation from Indonesia. Novavax also filed an application for approval of the vaccine in Canada and with the European Medicines Agency.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":28,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}